Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers

The report in this issue by Pomerantz and colleagues demonstrates that men with metastatic prostate cancer harboring germline BRCA2 mutations are strongly associated with a prostate-specific antigen response 50% during treatment with a platinum agent. However, more work will be required to classify other men who might benefit from platinum agents. See also pages 3532-9.